Mumbai: Sun Pharma reported the consolidated net income of Rs 1,444 Crore for the quarter that ended in June such as the Net Loss of Rs 1,655 Crore in the second quarter, supported by strong sales in the main market including India and the US.
Consolidated sales of operations reached Rs 9,669 Crore, 29% growth over Q1 in the previous year and 14% over Q4 before, said a company statement.
The sale of branded formulations in India for Q1FY22 is Rs 3,308 Crore, up 39%, and takes into account 34% of total sales.
While US sales were $ 380 million, growth of 35% more than last year and 3% sequential, accounting of around 29% of total sales.
Sun Pharma MD Dilip Shanghvi said, “We watched a strong Q1.”